How much is a CDMO stock worth?
One share of CDMO stock can currently be purchased for approximately $19.36. How much money does Avid Bioservices make? Avid Bioservices has a market capitalization of $1.19 billion and generates $95.87 million in revenue each year.
What price target do analysts set for CDMO?
What price target have analysts set for CDMO? 3 analysts have issued 1 year target prices for Avid Bioservices' stock. Their forecasts range from $28.00 to $35.00. On average, they anticipate Avid Bioservices' stock price to reach $31.67 in the next year.
What happened to Avid Bioservices (CDMO) stock?
Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session. In the latest trading session, Avid Bioservices (CDMO) closed at $21.54, marking a -1.6% move from the previous day.
What does cdmop stand for?
Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies,...
See more
Should I buy or sell Avid Bioservices stock right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 4 buy rati...
What is Avid Bioservices' stock price forecast for 2022?
4 Wall Street analysts have issued 12 month price targets for Avid Bioservices' stock. Their forecasts range from $28.00 to $32.00. On average, the...
How has Avid Bioservices' stock performed in 2022?
Avid Bioservices' stock was trading at $29.18 at the beginning of the year. Since then, CDMO shares have decreased by 54.2% and is now trading at $...
When is Avid Bioservices' next earnings date?
Avid Bioservices is scheduled to release its next quarterly earnings announcement on Tuesday, July 5th 2022. View our earnings forecast for Avid B...
How were Avid Bioservices' earnings last quarter?
Avid Bioservices, Inc. (NASDAQ:CDMO) released its quarterly earnings data on Tuesday, December, 7th. The biopharmaceutical company reported $0.06 e...
When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?
Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. Th...
What guidance has Avid Bioservices issued on next quarter's earnings?
Avid Bioservices updated its FY 2022 earnings guidance on Tuesday, April, 5th. The company provided earnings per share (EPS) guidance of for the pe...
Who are Avid Bioservices' key executives?
Avid Bioservices' management team includes the following people: Mr. Nicholas Stewart Green B.Sc. , MBA, Pres, CEO & Director (Age 57, Pay $1.55...
What is Roger Lias' approval rating as Avid Bioservices' CEO?
2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com . Roger Lias has an approval rating of 49% among Avid Bioservices' employe...
Signals & Forecast
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 18.52%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices.
Support, Risk & Stop-loss
Avid Bioservices Inc. finds support from accumulated volume at $19.36 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Avid Bioservices Inc. stock A Buy?
Avid Bioservices Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are positive buying more shares than they are selling in Avid Bioservices Inc
In the last 100 trades there were 606.3 thousand shares bought and 437.68 thousand shares sold. The last trade was done 13 days ago by Ziebell Mark R who sold 6.43 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know
Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session.
Here's Why Avid Bioservices (NASDAQ:CDMO) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Avid Bioservices (CDMO)
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Avid Bioservices, Inc. - Hold
Zacks' proprietary data indicates that Avid Bioservices, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the CDMO shares relative to the market in the next few months. In addition, Avid Bioservices, Inc.
Style Scorecard
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
Chart for CDMO
Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture.
